# Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

> **NCT03710564** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 535 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** Brolucizumab
- **BIOLOGICAL:** Aflibercept

## Key facts

- **NCT ID:** NCT03710564
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-30
- **Primary completion:** 2020-12-21
- **Final completion:** 2021-07-01
- **Target enrollment:** 535 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710564, "Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT03710564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*